Early Symptoms of Ebola and Hantavirus Resemble Flu, Prompting Urgent Detection Measures

Both Ebola and hantavirus infections can begin with symptoms similar to those of the flu, underscoring the need for prompt recognition and rigorous infection control to reduce the risk of spread and improve patient outcomes.

These two viral diseases have recently attracted increased attention due to their potential severity and public health significance. Despite their differences, Ebola and hantavirus share early clinical presentations and require stringent infection prevention and control (IPAC) protocols to mitigate transmission risks.

To assist healthcare providers in identifying and managing these infections, two brief articles published on June 22, 2026, in the Canadian Medical Association Journal (CMAJ) present updated recommendations on diagnosis, treatment, and infection control for each disease.

Hantavirus Transmission and Clinical Features

In Canada, hantavirus is a nationally notifiable illness, mandating that all confirmed cases be reported to public health officials. Approximately four to five cases are confirmed annually, primarily associated with rodent exposure in agricultural regions of Manitoba, Saskatchewan, Alberta, and British Columbia. Notably, the Andes virus strain stands out for its capacity for human-to-human transmission.

Clinical manifestations vary by hantavirus strain. In the Americas, including infections caused by the Andes virus, hantavirus cardiopulmonary syndrome is typical. Conversely, European and Asian strains generally induce hemorrhagic fever accompanied by kidney dysfunction. Both forms have incubation periods ranging from two to four weeks before symptom onset, which commonly includes fever, headache, muscle pain, and abdominal discomfort.

Diagnosis relies on serological assays and polymerase chain reaction (PCR) testing, conducted by the National Microbiology Laboratory in Winnipeg. Currently, there are no approved antiviral therapies or vaccines for hantavirus; management centers on supportive care to alleviate symptoms and aid recovery.

Infection Control for Hantavirus Cases

Given the potential for person-to-person spread with the Andes strain, suspected hantavirus cases require strict infection prevention measures. Patients should be isolated using airborne, droplet, and contact precautions. Care should involve infectious disease specialists, and public health authorities must be promptly informed.

Ebola Virus Disease Overview and Transmission

Since its identification in 1976, Ebola virus disease has caused recurrent outbreaks in Central and West Africa. Three primary Ebola viruses infect humans, with fruit bats believed to be the natural reservoir. Transmission occurs through direct contact with bodily fluids such as blood, vomit, diarrhea, and semen, as well as contact with contaminated surfaces and objects.

The ongoing outbreak in the Democratic Republic of Congo involves Bundibugyo ebolavirus, which has a fatality rate estimated between 30% and 50%. While hemorrhagic symptoms are commonly associated with Ebola, less than half of patients exhibit bleeding. Early signs more frequently include fever above 38°C, fatigue, muscle aches, and gastrointestinal symptoms. The incubation period ranges from two to 21 days, with PCR testing used to confirm diagnosis.

Testing and Protective Measures for Ebola

Individuals presenting compatible symptoms who have recently traveled to Ebola-affected countries or had close contact with infected persons, bats, primates, or game animals from these regions should undergo evaluation and testing. Health Canada advises comprehensive infection prevention and control protocols for suspected Ebola cases, including screening procedures and the use of full personal protective equipment (PPE) such as fit-tested N95 respirators, face shields, gloves, and fluid-impermeable protective clothing.

Advances and Limitations in Ebola Treatment

Significant progress has been made against certain Ebola virus strains. Vaccines with high efficacy are available to prevent Zaire ebolavirus infection, and two antiviral medications have reduced mortality rates from approximately 50% to 35%. However, no approved vaccines or treatments currently exist for Bundibugyo ebolavirus, making supportive care the mainstay for patients infected with this strain.

References:

“Ebola virus disease” by Maxime J. Billick, William K. Silverstein and Isaac I. Bogoch, Canadian Medical Association Journal, June 22, 2026. DOI: 10.1503/cmaj.260834

“Hantavirus” by Marie-Laure Oberweis, Ana C. Blanchard and Esther Vaugon, Canadian Medical Association Journal, June 22, 2026. DOI: 10.1503/cmaj.260789